1995: The year of the calcium antagonist controversy

Current Opinion in Nephrology and Hypertension

Volumn 5, Issue 3, 1996, Pages 214-218

  Cohen, Jerome D ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DIURETIC AGENT; NIFEDIPINE;

ANTIHYPERTENSIVE THERAPY; CORONARY RISK; DRUG SAFETY; HEART INFARCTION; HUMAN; HYPERTENSION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

CALCIUM CHANNEL BLOCKERS; HUMANS; HYPERTENSION; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; NIFEDIPINE;

EID: 0030002556     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-199605000-00005     Document Type: Review

References (34)

1. Rutan GH, Cushman WC: Relative benefits of different antihypertensive drugs in the prevention of vascular complications. Curr Opin Nephrol Hypertens 1995, 4:240-244.
2. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Lemaitre R, Smith NL, Wahl PW, Wagner EH, Furberg CD: The risk of incident myocardial infarction associated with anti-hypertensive drug therapies [Abstract 18]. Circulation 1995, 91:925.
3. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, Rosendaal FR, Lemaitre RN, Smith NL, Wahl PW et al.: The risk of myocardial infarction associated with anti-hypertensive drug therapies. JAMA 1995, 274:620-625. A case-control study suggesting that calcium antagonists in the treatment of hypertension are asociated with a higher risk of myocardial infarction than diuretics or beta-blockers, and that this may be a dose-response relationship.
4. ••], and especially, the problem of confounding data based on selection bias.
5. Furberg CD, Psaty BM, Meyer JV: Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995, 92:1326-1331. A meta-analysis study of nifedipine trials in patients with acute coronary syndromes, showing that short-acting nifedipine, especially at high doses was associated with an increased rate of mortality.
6. ••] and suggesting it was flawed for several reasons including the selection of data, statistical methods and extrapolation of findings from one short-acting dihydropyridine drug to other drugs.
7. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW: Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators. Lancet 1990, 335:1109-1113.
8. ••] and questioning the methodology of the study and the applicability to patients with chronic angina and to newer calcium antagonists.
9. Myers MG: Dihydropyridine calcium antagonists and the trough: peak ratio: focus on adverse effects. J Hypertens 1994, 12(suppl 8):S73-S77.
10. ••] indicating that findings are consistent with previous studies and that the dose-response effects provide compelling evidence of a causal association.
11. Horton R: Spinning the risks and benefits of calcium antagonists. Lancet 1995, 346:586-587.
12. Messerli FH: Are calcium antagonists safe? [Letter]. Lancet 1995, 346:767-768.
13. Macdonald G: Are calcium antagonists safe? [Letter]. Lancet 1995, 346:768.
14. Brown MJ: Are calcium antagonists safe? [Letter]. Lancet 1995, 346:769.
15. Poole-Wilson PA: Are calcium antagonists safe? [Letter]. Lancet 1995, 346:769-770.
16. Horton R: Are calcium antagonists safe? [Letter]. Lancet 1995, 346:770.
17. Messerli FH: Case-control study, meta-analysis, and bouillabaisse: putting the calcium antagonist scare into context. Ann Intern Med 1995, 123:888-889.
18. Yusuf S, Held P, Furberg C: Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT III) and other recent studies. Am J Cardiol 1991, 67:1295-1297.
19. The Danish Study Group on Verapamil in Myocardial Infarction: Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish verapamil Infarction Trial II - DAVIT II). Am J Cardiol 1990, 66:779-785.
20. Gibson RS, Boden WE, Theroux P, Strauss HD, Pratt CM, Gheorghiade M, Capone RJ, Crawford MH, Schlant RC, Kleiger RE: Diltiazem and reinfarction in patients with non-Q wave myocardial infarction: results of a double-blind randomized, multicenter trial. N Engl J Med 1986, 315:423-429.
21. Ruzicka M, Leenen FHH: Relevance of intermittent increases in sympathetic activity for adverse outcome on short-acting calcium antagonists. In Hypertension, pathophysiology, diagnosis and management. Edited by Laragh JH, Brenner BM. New York, New York: Raven Press; 1995:2815-2825.
22. Stone PH, Muller JE, Turi ZG, Geltman E, Jaffe AS, Braunwald E: Effect of nifedipine therapy in patients with refractory angina pectoris: significance of the presence of coronary spasm. Am Heart J 1983, 106:644-652.
23. Egstrup K, Anderson PE: Transient myocardial ischemia during nifedipine therapy in stable angina pectoris, and its relation to coronary collateral flow and comparison with metoprolol. Am J Cardiol 1993, 71:177-183.
24. Francis GS: Calcium channel blockers and congestive heart failure. Circulation 1991, 83:336-338.
25. Packer M: Pathophysiological mechanisms underlying the adverse effects of calcium channel-blocking drugs in patients with chronic heart failure. Circulation 1989, 80:59-67.
26. Elkayam U, Amin J, Mehra A, Vasquez J, Weber L, Rahimtoola SH: A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 1990, 82:1954-1961.
27. O'Connor CM, Belkin RN, Carson PE, Cropp AB, Frid DJ, Miller AB, Neuberg GW, Pressler ML, Wertheimer JH, Packer M: Effect of amlodipine on mode of death in severe chronic heart failure: the PRAISE Trial [Abstract 0676]. Circulation 1995, 92:1-143.
28. Cohn JN, Ziesche SM, Loss LE, Anderson GF and the V-HeFT Study Group, University of Minnesota, Minneapolis, MA: Effect of felodipine on short-term exercise and neurohormone and long-term mortality in heart failure: results of V-HeFT III [Abstract 0677]. Circulation 1995, 92:1-143.
29. Wagenknecht LE, Furberg CD, Hammon JW, Legault C, Troost BT: Surgical bleeding: unexpected effect of a calcium antagonist. BMJ 1995, 310:776-777.
30. Dahlof B, Hansson L, Lindholm LH, Schersten B, Wester PO, Ekbom T, Medner T, de Faire U: STOP - hypertension 2: a prospective intervention trial of newer versus older treatment alternatives in old patients with hypertension: Swedish Trial of Old Patients with Hypertension. Blood Pressure 1993, 2:136-141.
31. Staessen J, Bert P, Bulpitt C, De Cort P, Fagard R, Fletcher A, Livinen P, Lehtomaki E, Leonetti G, O'Brien E: Nitrendipine in older patients with isolated systolic hypertension: second progress report on the SYST-EUR trial. J Hum Hypertens 1993, 7:265-271.
32. The NORDIL Group: The Nordic Diltiazem Study (NORDIL): a prospective intervention trial of calcium antagonist therapy in hypertension. Blood Pressure 1993, 2:314-321.
33. Hansson L, Zanchetti A for the HOT Study Group: The Hypertension Optimal Treatment (HOT) Study - patient characteristics: randomization, risk profiles and early blood pressure results. Blood Pressure 1994, 3:322-327.
34. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT, Cushman WC, Grimm RH, LaRosa J, Whelton PK, Perry HM: Rationale and design for the Anti-hypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens 1996 (in press).